Newsroom
  • Press Releases
  • Presentations
Investors
  • Overview
  • Annual Meeting of Stockholders
  • Warrant Exercise Inquiries
  • Restricted Stock Inquiries
  • News / Events
  • Company Information
  • Financial Information
  • Stock Data
  • SEC Filings
  • Corporate Governance
Contact

CytoDyn Inc.

  • Home
  • About CytoDyn
    • Meet CytoDyn
  • Our Science
  • Pipeline
  • Our Team
    • Leadership Team
    • Board of Directors
  • Publications
  • Scientific Advisory Board
  • Newsroom
  • Investors
  • Contact
Latest News

Press Releases

Newsroom

Newsroom

  • Press Releases
  • Presentations

CytoDyn to Hold Webcast to Discuss the Performance of Leronlimab in Clinical Trials and Recent Charges Against Former CEO

Dec 23, 2022 8:00am EST

CytoDyn to Host R&D Update on Wednesday, December 7, 2022

Nov 22, 2022 8:30am EST

CytoDyn Announces Voluntary Withdrawal of BLA for HIV-MDR Due to CRO Data Management Issues

Oct 28, 2022 5:15pm EDT

CytoDyn Announces Appointment of Additional Directors with Industry Experience

Oct 20, 2022 8:30am EDT

CytoDyn to Hold Webcast to Provide a Quarterly Company Update

Sep 19, 2022 8:30am EDT

CytoDyn Appoints Cyrus Arman, Ph.D., MBA, as President

Jul 13, 2022 8:30am EDT

CytoDyn Highlights NIH Grant for HIV Functional Cure Preclinical Study of Gene Therapy Based on Leronlimab

Jul 11, 2022 8:30am EDT

CytoDyn to Hold Webcast to Provide a Quarterly Company Update

Jun 22, 2022 8:30am EDT

CytoDyn Announces Resolution of Legal Dispute with Former Chief Medical Officer

May 23, 2022 8:30am EDT

CytoDyn Announces the Addition of Leading Experts in Oncology, Infectious Diseases, and Neuroinflammation to its Scientific Board of Advisors; Dr. Jay Lalezari to Serve as Outside Scientific Advisor

May 13, 2022 8:00am EDT
RSS
  • 1
  • 2
Next
© 2023 CytoDyn Inc. All Rights Reserved.
  • Twitter
  • Facebookj
Privacy Policy Disclaimer Sitemap